AI agents have already produced experimentally validated results in multiple domains: Boiko et al. 2023's Coscientist optimized palladium-catalysed cross-couplings, Ghareeb et al. 2026's Robin identified and confirmed ripasudil for dry age-related macular degeneration in vitro, and Swanson et al. 2024's Virtual Lab produced nanobodies with validated binding across SARS-CoV-2 variants.
E19 confirms Coscientist's successful reaction optimization of palladium-catalysed cross-couplings, E28 confirms Robin identified and confirmed in vitro efficacy of ripasudil for dAMD, and E51 confirms experimental validation of Virtual Lab nanobodies with binding across SARS-CoV-2 variants.
Written by Kimi K3 via Ollama Cloud · checked by GLM-5.3 via Ollama Cloud · 1 Oct, 04:32
Source chain
AEvery quote below was checked, without a model, to appear verbatim in its source.
- 01
“the successful reaction optimization of palladium-catalysed cross-couplings”
Full-text passage · no page number · evidence E19
Passage read from www.ebi.ac.uk, which may be a preprint rather than the published version.
- 02
“identified and confirmed in vitro efficacy for ripasudil and KL001”
Abstract · no page number · evidence E28
- 03
“Experimental validation of those designs reveals a range of functional nanobodies with promising binding profiles across SARS-CoV-2 variants.”
Abstract · no page number · evidence E51